Deciphering the Genomic Landscape and Pharmacological Profile of Uncommon Entities of Adult Rhabdomyosarcomas

Adult rhabdomyosarcoma (RMS) represents an uncommon entity with an incidence of less than 3% of all soft tissue sarcomas (STS). Consequently, the natural history and the clinical management of this disease are infrequently reported. In order to fill this gap, we investigated the molecular biology of an adult RMS case series. The expression of epithelial mesenchymal transition-related gene and chemoresistance-related gene panels were evaluated. Moreover, taking advantage of our STS translational model combining patient-derived primary culture and 3D-scaffold, the pharmacological profile of an adult head and neck sclerosing RMS was assessed. Furthermore, NGS, microsatellite instability, and in silico analyses were carried out. RT-PCR identified the upregulation of CDH1, SLUG, MMP9, RAB22a, S100P, and LAPTM4b, representing promising biomarkers for this disease. Pharmacological profiling showed the highest sensitivity with anthracycline-based regimen in both 2D and 3D culture systems. NGS analysis detected RAB3IP-HMGA2 in frame gene rearrangement and FGFR4 mutation; microsatellite instability analysis did not detect any alteration. In silico analysis confirmed the mutation of FGFR4 as a promising marker for poor prognosis and a potential therapeutic target. We report for the first time the molecular and pharmacological characterization of rare entities of adult head and neck and posterior trunk RMS. These preliminary data could shed light on this poorly understood disease.

[1]  A. De Vita,et al.  Identification of a novel RAB3IP-HMGA2 fusion transcript in an adult head and neck rhabdomyosarcoma. , 2021, Oral diseases.

[2]  A. De Vita,et al.  Molecular Determinants of Soft Tissue Sarcoma Immunity: Targets for Immune Intervention , 2021, International journal of molecular sciences.

[3]  A. De Vita,et al.  The potential role of the extracellular matrix in the activity of trabectedin in UPS and L-sarcoma: evidences from a patient‐derived primary culture case series in tridimensional and zebrafish models , 2021, Journal of experimental & clinical cancer research : CR.

[4]  A. De Vita,et al.  Three-dimensional collagen-based scaffold model to study the microenvironment and drug-resistance mechanisms of oropharyngeal squamous cell carcinomas , 2021, Cancer biology & medicine.

[5]  A. De Vita,et al.  Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer , 2021, Scientific Reports.

[6]  Narasimhan P. Agaram,et al.  Head and neck rhabdomyosarcoma with TFCP2 fusions and ALK overexpression: a clinicopathological and molecular analysis of 11 cases , 2020, Histopathology.

[7]  D. Amadori,et al.  Lineage‐specific mechanisms and drivers of breast cancer chemoresistance revealed by 3D biomimetic culture , 2020, Molecular oncology.

[8]  M. Rugge,et al.  Impact of Rhabdomyosarcoma Treatment Modalities by Age in a Population-Based Setting. , 2020, Journal of adolescent and young adult oncology.

[9]  B. Casini,et al.  Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group , 2020, Frontiers in Oncology.

[10]  Zhen Zhang,et al.  The survival benefit of radiotherapy in localized primary adult rhabdomyosarcoma , 2020, Asia-Pacific journal of clinical oncology.

[11]  D. Amadori,et al.  A biomimetic 3D model of hypoxia-driven cancer progression , 2019, Scientific Reports.

[12]  W. Frankel,et al.  Microsatellite Instability Occurs in a Subset of Follicular Thyroid Cancers. , 2019, Thyroid : official journal of the American Thyroid Association.

[13]  A. Ferrari,et al.  Rhabdomyosarcoma , 2019, Nature Reviews Disease Primers.

[14]  Narasimhan P. Agaram,et al.  MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification , 2018, Modern Pathology.

[15]  J. Blay,et al.  Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study , 2018, Cancer medicine.

[16]  M. Amgad,et al.  Management of Low and Intermediate Risk Adult Rhabdomyosarcoma: A Pooled Survival Analysis of 553 Patients , 2018, Scientific Reports.

[17]  M. Kortylewski,et al.  SNAIL is a key regulator of alveolar rhabdomyosarcoma tumor growth and differentiation through repression of MYF5 and MYOD function , 2018, Cell Death & Disease.

[18]  H. Masuyama,et al.  Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability , 2018, PloS one.

[19]  D. Amadori,et al.  Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma. , 2018, Journal of visualized experiments : JoVE.

[20]  C. Antonescu,et al.  Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. , 2018, The Lancet. Oncology.

[21]  M. Sawyer,et al.  Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D. Amadori,et al.  Primary Culture of Undifferentiated Pleomorphic Sarcoma: Molecular Characterization and Response to Anticancer Agents , 2017, International journal of molecular sciences.

[23]  D. Amadori,et al.  Management and potentialities of primary cancer cultures in preclinical and translational studies , 2017, Journal of Translational Medicine.

[24]  D. Amadori,et al.  Myxofibrosarcoma primary cultures: molecular and pharmacological profile , 2017, Therapeutic advances in medical oncology.

[25]  Russell Bonneville,et al.  Landscape of Microsatellite Instability Across 39 Cancer Types. , 2017, JCO precision oncology.

[26]  J. Desai,et al.  Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. , 2017, The Lancet. Oncology.

[27]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[28]  D. Amadori,et al.  Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas , 2017, OncoTargets and therapy.

[29]  D. Amadori,et al.  CORRECTION: Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model , 2017, Biology Open.

[30]  D. Amadori,et al.  Activity of Eribulin in a Primary Culture of Well-Differentiated/Dedifferentiated Adipocytic Sarcoma , 2016, Molecules.

[31]  D. Amadori,et al.  Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas , 2016, OncoTargets and therapy.

[32]  James R. Eshleman,et al.  Microsatellite Instability as a Biomarker for PD-1 Blockade , 2016, Clinical Cancer Research.

[33]  Robin L. Jones,et al.  Adult Pleomorphic Rhabdomyosarcoma: A Multicentre Retrospective Study. , 2015, Anticancer research.

[34]  Suresh C. Sharma,et al.  Adult rhabdomyosarcoma: Clinical presentation, treatment, and outcome. , 2015, Journal of cancer research and therapeutics.

[35]  S. Richman Deficient mismatch repair: Read all about it (Review) , 2015, International journal of oncology.

[36]  B. Vogelstein,et al.  PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  T. Yamashita,et al.  Prognostic impact of CD109 expression in myxofibrosarcoma , 2015, Journal of surgical oncology.

[38]  G. Getz,et al.  Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. , 2014, Cancer discovery.

[39]  G. Johnson,et al.  Implications of Mesenchymal Cells in Cancer Stem Cell Populations: Relevance to EMT , 2014, Current Pathobiology Reports.

[40]  C. Keller,et al.  MDM2 Amplification and PI3KCA Mutation in a Case of Sclerosing Rhabdomyosarcoma , 2013, Sarcoma.

[41]  J. Jagannathan,et al.  Imaging features of primary and secondary adult rhabdomyosarcoma. , 2012, AJR. American journal of roentgenology.

[42]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[43]  J. Wanders,et al.  A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours , 2012, British Journal of Cancer.

[44]  J. Merks,et al.  Imaging findings in craniofacial childhood rhabdomyosarcoma , 2010, Pediatric Radiology.

[45]  Alan Wells,et al.  Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition , 2010, Molecular Cancer.

[46]  S. Altekruse,et al.  Outcomes for children and adolescents with cancer: challenges for the twenty-first century. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  N. Dalay,et al.  Assessment of microsatellite instability in head and neck cancer using consensus markers , 2010, Molecular Biology Reports.

[48]  A. Montpetit,et al.  SNP genotyping of a sclerosing rhabdomyosarcoma: reveals highly aneuploid profile and a specific MDM2/HMGA2 amplification. , 2009, Human pathology.

[49]  R. Weinberg,et al.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits , 2009, Nature Reviews Cancer.

[50]  N. Sebire,et al.  Rhabdomyosarcoma Subtyping by Immunohistochemical Assessment of Myogenin: Tissue Array Study and Review of the Literature , 2008, Pathology & Oncology Research.

[51]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[52]  James R. Anderson,et al.  Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  S. Spunt,et al.  Soft tissue sarcomas of childhood. , 2004, Cancer treatment reviews.

[54]  P. Navarria,et al.  Rhabdomyosarcoma in adults , 2003, Cancer.

[55]  S. Tripp,et al.  Are Myogenin and MyoD1 Expression Specific for Rhabdomyosarcoma?: A Study of 150 Cases, With Emphasis on Spindle Cell Mimics , 2001, The American journal of surgical pathology.

[56]  James R. Anderson,et al.  Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  T. Mentzel,et al.  Pleomorphic Rhabdomyosarcoma in Adults: A Clinicopathologic Study of 38 Cases with Emphasis on Morphologic Variants and Recent Skeletal Muscle-Specific Markers , 2001, Modern Pathology.

[58]  Jonathan J. Lewis,et al.  Clinicopathologic analysis of patients with adult rhabdomyosarcoma , 2001, Cancer.

[59]  J. Epstein,et al.  E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. , 1999, Urology.

[60]  T. D. Hamilton,et al.  Classification of Tumours , 1930, Edinburgh medical journal.

[61]  Yon E.udolpii On Tumours , 1864, The British and Foreign Medico-Chirurgical Review.

[62]  F. Roviello,et al.  KRAS Mutation in Gastric Cancer and Prognostication Associated with Microsatellite Instability Status , 2017, Pathology & Oncology Research.

[63]  T. Group,et al.  Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group , 2016, Annals of Surgical Oncology.

[64]  J. Vieweg,et al.  E-cadherin plasticity in prostate cancer stem cell invasion. , 2011, American journal of cancer research.

[65]  T. Boulikas,et al.  Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study. , 2007, Anticancer research.

[66]  G R Wilkinson,et al.  Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. , 1984, Cancer research.

[67]  博之 伊藤,et al.  急激に発生した篩骨洞 rhabdomyosarcoma 症例 , 1979 .